QRG Capital Management Inc. Decreases Stock Position in Sanofi $SNY

QRG Capital Management Inc. reduced its position in shares of Sanofi (NASDAQ:SNY) by 36.0% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 93,954 shares of the company’s stock after selling 52,873 shares during the quarter. QRG Capital Management Inc.’s holdings in Sanofi were worth $4,435,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in SNY. Callodine Capital Management LP increased its stake in shares of Sanofi by 26.9% during the second quarter. Callodine Capital Management LP now owns 515,209 shares of the company’s stock valued at $24,890,000 after purchasing an additional 109,240 shares in the last quarter. Equity Investment Corp increased its stake in Sanofi by 2.5% during the 2nd quarter. Equity Investment Corp now owns 2,512,435 shares of the company’s stock valued at $121,376,000 after purchasing an additional 62,109 shares in the last quarter. Osaic Holdings Inc. raised its holdings in Sanofi by 17.0% in the 2nd quarter. Osaic Holdings Inc. now owns 188,526 shares of the company’s stock worth $9,189,000 after acquiring an additional 27,427 shares during the last quarter. CGN Advisors LLC bought a new position in Sanofi in the 2nd quarter valued at approximately $1,694,000. Finally, Simon Quick Advisors LLC bought a new position in Sanofi in the 2nd quarter valued at approximately $246,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY opened at $46.59 on Monday. The stock has a market capitalization of $113.63 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 1.16 and a beta of 0.45. The company has a fifty day moving average of $49.00 and a 200 day moving average of $48.84. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.30 and a current ratio of 1.06. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 24th. The company reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $1.31. The company had revenue of $15.46 billion for the quarter, compared to the consensus estimate of $12.62 billion. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.25 earnings per share. As a group, sell-side analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. Guggenheim cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Cowen restated a “hold” rating on shares of Sanofi in a research note on Tuesday, December 30th. HSBC reaffirmed a “buy” rating on shares of Sanofi in a research report on Wednesday, December 10th. Jefferies Financial Group reiterated a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a research report on Monday, December 8th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.67.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.